Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.
Evotec SE reports developments in drug discovery and development services, integrated R&D programs and strategic partnerships with pharmaceutical, biotechnology, academic and health-focused organizations. Its updates commonly cover small-molecule, biologics and cell-therapy work; AI/ML-enabled platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling; and therapeutic programs in oncology, cardiovascular and metabolic disease, neurology, immunology and infectious disease.
Recurring news also includes Just - Evotec Biologics manufacturing and biologics-development activity, grant-funded global-health work, preclinical candidate nominations, financial results and business updates. Governance items include Supervisory Board nominations, management appointments and operating-model changes tied to the company’s global R&D and partnership infrastructure.
Evotec (NASDAQ:EVO) placed senior unsecured convertible bonds due 2033 with an aggregate principal amount of €116.1 million. The seven-year Bonds, with an investor put after five years, carry a 2.625% coupon and will be redeemed at 110% of principal, implying a 3.882% yield.
The initial conversion price is €6.5313, a 37.5% premium to the €4.75 reference price, with an effective conversion price of about €7.1844 at maturity. Net proceeds are intended to fund Project Horizon, Evotec’s transformation program.
Evotec (NASDAQ:EVO) announced nomination of a small‑molecule preclinical development candidate (PDC) from its dermatology collaboration with Almirall on May 4, 2026. The joint team advanced from initial leads to PDC in about two years, using Evotec's AI/ML‑enhanced discovery and preclinical platforms and will support IND enabling via the INDiGO platform.
The program targets immune‑mediated inflammatory skin diseases and combines Evotec's end‑to‑end discovery capabilities with Almirall's dermatology expertise to progress the candidate toward clinical readiness.
Evotec (NASDAQ:EVO) received two Gates Foundation grants totaling $9.9 million to support tuberculosis drug discovery and translational development over 24–25 months. The awards fund AI‑enabled discovery of novel small molecules and nonclinical evaluation of advanced TB drug combinations, including Long Acting Injectables, to accelerate candidate selection and de‑risk progression to clinical testing.
Evotec (NASDAQ:EVO) nominated Dr. Wolfgang Hofmann for election as an independent Supervisory Board member and proposed expanding the Supervisory Board from six to seven members.
The company announced a cooperation agreement with key shareholder MAK Capital that includes customary voting and cooperation commitments. The AGM is scheduled for June 11, 2026.
Evotec (NASDAQ:EVO) will announce its first quarter 2026 results and provide a business update on Wednesday, May 6, 2026. A live webcast and conference call in English will start at 14:00 CEST (08:00 EDT). Registered participants receive dial-in details and slides; an on-demand replay will be available on the company website.
Evotec (NASDAQ:EVO) announced that Chief Financial Officer Paul Hitchin will step down effective April 30, 2026 for personal reasons, and that Claire Hinshelwood will become CFO effective May 1, 2026.
Ms. Hinshelwood brings 30+ years of financial leadership, including roles as Group CFO of BMI Group and Global Head of Finance Operations at Novartis. Mr. Hitchin led Evotec's financial transformation since March 1, 2025.
Evotec (NASDAQ:EVO) appointed Dr. Ingrid Müller as Chief Operating Officer, joining the Management Board effective May 1, 2026. Dr. Müller brings more than 20 years of international life‑sciences leadership across operations, strategy, supply and R&D integration and will lead the Horizon initiative execution.
Her remit covers quality, productivity, scalability, delivery, cost and technology improvements to support partner delivery and Evotec's growth transformation.
Evotec (NASDAQ:EVO) nominated Dieter Weinand as Supervisory Board Chairman, proposed for election at the June 11, 2026 Annual General Meeting. The move succeeds Prof. Dr. Iris Löw-Friedrich and aims to strengthen commercial execution, strategic partnerships and long-term value creation while Weinand reduces outside board seats to ensure focus.
Evotec (NASDAQ:EVO) will report fourth-quarter and full-year 2025 results and provide a business update via webcast and conference call on April 8, 2026.
The live webcast starts at 2:00 pm CEST (8:00 am EDT); registration is required to access the audio, presentation slides, and dial-in details. An on-demand replay will be available on the company website.
Evotec (NASDAQ:EVO) named Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer on April 1, 2026.
Dr. Khan brings over 15 years of international leadership and a track record of closing $7 billion+ in deals; he previously served at Iktos, Proteros and Schrödinger. Evotec has >4,800 employees and >100 proprietary R&D assets.